In a report released today, Matthew O’Brien from Piper Sandler maintained a Buy rating on Integer Holdings (ITGR – Research Report), with a price target of $115.00. The company’s shares closed yesterday at $100.18.
According to TipRanks, O’Brien is a 5-star analyst with an average return of 7.0% and a 52.16% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Sight Sciences, Atricure, and Integer Holdings.
Integer Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $107.60, implying a 7.41% upside from current levels. In a report released on February 16, Benchmark Co. also maintained a Buy rating on the stock with a $105.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
ITGR market cap is currently $3.29B and has a P/E ratio of 37.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Integer Holdings (ITGR) Company Description:
Integer Holdings Corp. engages in manufacturing and developing of medical devices and components. It operates through the Medical and Non-Medical segments. The Medical segment include cardio and vascular; cardiac and neuromodulation; and advanced surgical, orthopedics, and portable medical. The Non-Medical segment provides battery packs to the energy, military, and environmental markets for use in extreme environments, with the Electrochem as its product. The firm’s products include batteries, capacitors, catheters, and guidewires. The company was founded by Wilson Greatbatch in 1970 and is headquartered in Plano, TX.
Read More on ITGR:
- A New Cause for Concern: Integer Holdings Adds a New Debt & Financing Risk
- Integer management to meet with Piper Sandler
- Integer Holdings Unveils Updated Earnings Presentation for 2023
- Integer Holdings Corporation Reports Results for Fourth Quarter and Full Year 2023
- Integer sees FY24 adjusted EOS $5.01-$5.43, consensus $5.45
